Generic Verzenio (Abemaciclib)

Abemaciclib is the active ingredient in Verzenio® (marketed as Verzenios® in some regions), Eli Lilly's CDK4/6 inhibitor for hormone-receptor-positive, HER2-negative breast cancer. Generic abemaciclib contains the same active ingredient at the same strengths and is produced by licensed pharmaceutical manufacturers. For patients paying out of pocket, the generic can cost significantly less than the originator brand. Used as prescribed by a licensed medical professional.

Verzenio® is the originator brand name for abemaciclib, developed by Eli Lilly. It is a targeted oncology therapy prescribed in the management of hormone-receptor-positive (HR-positive), HER2-negative breast cancer — in advanced or metastatic disease and, in certain high-risk cases, as part of early breast-cancer treatment. It is almost always used together with endocrine (hormone) therapy such as an aromatase inhibitor or fulvestrant. As a prescription-only medicine, it is used under the supervision of a qualified oncologist.

Abemaciclib belongs to a class of medicines called CDK4/6 inhibitors. In simple terms, it blocks two proteins — cyclin-dependent kinases 4 and 6 — that hormone-receptor-positive breast-cancer cells use to divide. By interrupting this signal, the medicine is used as part of a treatment plan directed by your oncologist, typically combined with hormone therapy. Whether it is appropriate depends on your tumour type and hormone-receptor status, which your doctor confirms before treatment.

Abemaciclib is prescribed for adults with HR-positive, HER2-negative breast cancer, as confirmed by your oncology team. Your oncologist decides whether it is appropriate based on your diagnosis, hormone-receptor and HER2 status, prior treatments, and overall health, and whether it is used for advanced disease or as part of early-breast-cancer therapy.

For advanced or metastatic breast cancer, abemaciclib is commonly prescribed as 150 mg twice daily alongside endocrine therapy; the starting dose can differ when it is combined with certain hormone therapies. In high-risk early breast cancer it is typically taken twice daily for a defined period with hormone therapy. It can be taken with or without food, at about the same times each day. Your oncologist may reduce the dose or pause treatment to manage side effects such as diarrhoea or low blood counts. Always follow the dose your doctor prescribes.

Never change your dose on your own.

Reported side effects of abemaciclib may include diarrhoea (common, particularly early in treatment), low white-blood-cell counts, nausea, tiredness, reduced appetite, abdominal pain and anaemia. Less commonly, blood clots, liver-enzyme changes, or lung inflammation can occur, which is why your oncologist monitors you during treatment. Report severe or persistent diarrhoea, fever, breathlessness, or leg swelling promptly.

Report new or worsening symptoms to your doctor promptly. This is not a complete list — see the patient information leaflet.

Store as directed on the patient information leaflet, usually at room temperature away from moisture and out of reach of children. Always follow the storage guidance supplied with your medicine.

Abemaciclib is one of three CDK4/6 inhibitors used in HR-positive breast cancer. The others are palbociclib (the active ingredient in Ibrance) and ribociclib. A practical day-to-day difference is the dosing schedule: abemaciclib is usually taken continuously twice a day, whereas palbociclib and ribociclib are typically taken for three weeks followed by a one-week break. Their common side-effect patterns also differ — abemaciclib is more associated with diarrhoea, while the others are more associated with low white-blood-cell counts. Which medicine is appropriate is a decision only your oncologist can make. This page is for cost and access information, not for choosing a therapy.

Branded Verzenio carries the cost of the original research, clinical trials, and global marketing that brought abemaciclib to market, protected for years by patents. In countries where patents have expired or where generics are produced under licence, licensed pharmaceutical manufacturers can make the identical active ingredient without those overheads, which is why generic abemaciclib is typically priced far lower. The medicine itself is the same molecule at the same strength. For patients paying out of pocket, or where the brand is not reimbursed, this price gap is often what makes continuing treatment possible — which is why so many people search for the cost of abemaciclib and affordable generic options.

Abemaciclib is a long-term daily therapy that your oncology team monitors closely. Because diarrhoea is common — especially in the first weeks — your doctor will usually advise keeping anti-diarrhoeal medicine on hand and staying well hydrated. Expect regular blood tests to watch blood counts and liver function, and report symptoms such as significant diarrhoea, fever, breathlessness, or signs of a blood clot (leg swelling, chest pain) promptly. Many people take abemaciclib for extended periods with manageable side effects, but never stop or change your dose on your own — any adjustment should be planned with your doctor.